Inflarx N V's Comment on Sales, Marketing and Customers
The company serves customers in the medical markets targeted for its product candidates, including GOHIBIC (vilobelimab). It faces challenges in obtaining coverage and adequate reimbursement from government-funded and private payors, impacting its revenue and profitability. The company has limited marketing, sales, and distribution capabilities. It initiated activities related to the FDA’s Emergency Use Authorization (EUA) for GOHIBIC in the United States but ceased active commercialization at the end of 2025 due to lack of commercial success. The company may need to establish or outsource marketing and sales functions to effectively commercialize its products.
InflaRx Pharmaceuticals Inc., a subsidiary of InflaRx N.V., a biopharmaceutical company specializing in anti-inflammatory therapeutics targeting the complement system, has recently introduced the InflaRx Commitment Program. This program aims to broaden access to their product GOHIBIC (vilobelimab) for eligible patients. Under this program, institutions that meet the eligibility requirements will be refunded for up to six administered inpatient doses (the full treatment course) of GOHIBIC for patients who were administered the drug in line with its Emergency Use Authorization (EUA) and sadly passed away due to COVID-19 in the intensive care unit.The COVID-19 pandemic has put immense strain on healthcare syste...
Inflarx N V’s Comment on Sales, Marketing and Customers
The company serves customers in the medical markets targeted for its product candidates, including GOHIBIC (vilobelimab). It faces challenges in obtaining coverage and adequate reimbursement from government-funded and private payors, impacting its revenue and profitability. The company has limited marketing, sales, and distribution capabilities. It initiated activities related to the FDA’s Emergency Use Authorization (EUA) for GOHIBIC in the United States but ceased active commercialization at the end of 2025 due to lack of commercial success. The company may need to establish or outsource marketing and sales functions to effectively commercialize its products.
Sources:
Inflarx N V’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Inflarx N V’s corporate clients.
For your research, we’ve provided 9 tables on Inflarx N V corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
